Featured products from Pharmaceutical Technology's monthly newsletter, Equipment & Processing Report
Aspen Technology
Software enables faster optimization and improved plant safety for manufacturing process.
Aspen Techology’s latest release of its flagship software, aspenONE V8.3, includes new functionality in the Aspen HYSYS process simulation software that allows process engineers to size pressure safety valves (PSV) as an integral part of the overall process design. This feature allows calculation of necessary safety valve sizing specifications, including relief loads and orifice size. Process data can be used to analyze multiple overpressure scenarios, and a documentation-builder tool creates data and summary sheets. Another new feature, silent-install deployment, speeds software deployment.
Schenck AccuRate
A feeder’s disposable feed hopper shortens cleaning time and reduces cross-contamination.
The Schenck AccuRate AP-300 PureFeed feeder is designed for quick and easy disassembly, a dual-arm agitation system for maximizing material handling versatility, and an FDA-compliant feed hopper that is disposable and recyclable. The disposable feed hopper allows shorter cleaning cycles and virtually no chance of cross-contamination when moving from one material to another. The PureFeed AP-300 is available in volumetric and gravimetric configurations for pharmaceutical and nutraceutical applications with feed rates from 0.5 to approximately 150 kg/h.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.